Per- and polyfluoroalkyl substances (PFAS) are heavy environmental polluters due to their minimal environmental degradation. Phasing out these ‘forever chemicals’ is therefore a key priority for human and planetary health. It is estimated that around one-third (~37%) of total PFAS load to the environment originates from the medical sector. This is at odds with the (public) health goals that the healthcare system pursues. Therefore, reducing PFAS in healthcare should be a top priority, despite regulatory pressure targeting primarily other sectors.
Given the widespread use in healthcare, but lack of precise knowledge about the where, when and how, this co-created and interdisciplinary project will use the Amsterdam University Medical Center (UMC) as a ‘living lab’ to identify PFAS-containing products/applications, assess (non-)essential uses, and substitutability by safe-and-sustainable by design (SSbD) alternatives. It also explores the effect of such replacements on lowering the environmental burden, and sketch implications beyond Amsterdam UMC, such as other healthcare organizations and actors in the medical sector and supply chains.